Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07322094 · ClinicalTrials.gov registry record · Phase 1
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
A Phase 1 study of Primary Peritoneal Cancer and Fallopian Tube Cancers, sponsored by TORL Biotherapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT07322094: Recruiting Phase 1 study of Primary Peritoneal Cancer and Fallopian Tube Cancers, sponsored by TORL Biotherapeutics.
NCT07322094 is a Phase 1 study of Primary Peritoneal Cancer and Fallopian Tube Cancers that is actively recruiting participants, run by TORL Biotherapeutics. The registered enrollment target is 60 participants, below the 150-participant average among 27 other Primary Peritoneal Cancer trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07322094, a Phase 1 study of Primary Peritoneal Cancer and Fallopian Tube Cancers, is actively recruiting participants, sponsored by TORL Biotherapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
A Phase 1B/2 Study to Investigate the Safety and Efficacy of TORL-1-23 with Chemotherapy Given Before Initial Surgery in Women with Advanced Stage Ovarian Cancer
Primary Outcome
Incidence of Grade greater than or equal to 3 (using CTCAE V5.0) treatment-emergent adverse event (TEAE) and related serious adverse event (SAE)
Conditions Studied
Interventions
- COMBINATION_PRODUCT TORL-1-23 and paclitaxel
- COMBINATION_PRODUCT TORL-1-23 and carboplatin
- COMBINATION_PRODUCT TORL-1-23, paclitaxel, and carboplatin
Study Locations (1)
California
- UCLA - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-12-10 |
| Est. Completion | 2028-01 |
| Phase | Phase 1 |
What NCT07322094 shows while recruiting
NCT07322094 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 150-participant average among 27 other Primary Peritoneal Cancer trials with a reported enrollment target (60% lower).
The record links to 3 conditions, with Primary Peritoneal Cancer appearing as the primary indexed condition, and to 3 interventions - of which TORL-1-23 and paclitaxel is the first listed.
NCT07322094 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07322094 about?
NCT07322094 is a clinical study titled "CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer". A Phase 1B/2 Study to Investigate the Safety and Efficacy of TORL-1-23 with Chemotherapy Given Before Initial Surgery in Women with Advanced Stage Ovarian Cancer
What is the current status of trial NCT07322094?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2025-12-10. Estimated completion is 2028-01.
What conditions does trial NCT07322094 study?
This clinical trial studies the following conditions: Primary Peritoneal Cancer, Fallopian Tube Cancers, FIGO Stage III and IV Ovarian Cancer.
What interventions are being tested in trial NCT07322094?
The interventions under investigation include: TORL-1-23 and paclitaxel (COMBINATION_PRODUCT), TORL-1-23 and carboplatin (COMBINATION_PRODUCT), TORL-1-23, paclitaxel, and carboplatin (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT07322094?
This trial is sponsored by TORL Biotherapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07322094 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Peritoneal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07322094's enrollment target sits among peer trials
60 15th of 27 higher than 12 of 27 other Primary Peritoneal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Primary Peritoneal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 1
-
Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
RECRUITING · Phase 1
-
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
RECRUITING · Phase 1
-
Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI